Enabling Rapid, Scientifically-Sound Decision Making
Our portfolio of Translational Platforms for oncology and inflammation provide insight and understanding about a drug's efficacy, pharmacological profile and patient response profile, reducing failure in the clinic, and supporting the selection of the right patients for the right therapy.
CrownBio’s fast-paced R&D programs are yielding novel, yet well-validated models, at the cutting-edge of disease research. Our unique MuPrime™ models, as well as human target expressing models (HuGEMM™) and hematopoietic stem cell (HSC) – patient-derived xenograft (PDX) models are leading the way in advanced immuno-oncology.
Drive Your Next Clinical Success
Read why PDX models and their use in human-surrogate Phase II-like trials are changing the paradigm for oncology drug development and biomarker discovery today.
We’re inspired to help our clients. Let’s talk about how we can help you.